Quantum-Si (NASDAQ:QSI) Given “Buy” Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Quantum-Si (NASDAQ:QSI) in a research note published on Wednesday,Benzinga reports. The brokerage currently has a $4.00 price objective on the stock.

Separately, Canaccord Genuity Group cut their price target on Quantum-Si from $1.50 to $1.00 and set a “hold” rating for the company in a report on Wednesday.

Quantum-Si Trading Up 2.1 %

Shares of NASDAQ QSI opened at $0.79 on Wednesday. The stock has a fifty day simple moving average of $0.86 and a two-hundred day simple moving average of $1.12. Quantum-Si has a 1-year low of $0.70 and a 1-year high of $2.43. The firm has a market cap of $112.65 million, a price-to-earnings ratio of -1.24 and a beta of 2.89.

Quantum-Si (NASDAQ:QSI) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.03. Quantum-Si had a negative return on equity of 35.42% and a negative net margin of 3,968.84%. The firm had revenue of $0.79 million during the quarter, compared to analyst estimates of $1.06 million. Analysts forecast that Quantum-Si will post -0.71 EPS for the current year.

Institutional Investors Weigh In On Quantum-Si

Several large investors have recently added to or reduced their stakes in QSI. XTX Topco Ltd bought a new stake in Quantum-Si during the second quarter valued at $25,000. Public Employees Retirement System of Ohio bought a new stake in Quantum-Si during the first quarter valued at $27,000. Bleakley Financial Group LLC bought a new stake in Quantum-Si during the first quarter valued at $28,000. SG Americas Securities LLC bought a new stake in Quantum-Si during the third quarter valued at $53,000. Finally, Virtu Financial LLC bought a new stake in Quantum-Si during the first quarter valued at $98,000. Institutional investors own 39.90% of the company’s stock.

About Quantum-Si

Quantum-Si incorporated, a life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS). The company's platform is comprised of the Platinum NGPS instrument; the Platinum Analysis Software service; and reagent kits and semiconductor chips for use with its instruments.